Next Article in Journal
Water-Saving Techniques and Practices for On-Farm Surface Irrigation Systems
Previous Article in Journal
Effects of Adper™ Scotchbond™ 1 XT, Clearfil™ SE Bond 2 and Scotchbond™ Universal in Odontoblastic Activity
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biology and Life Sciences Forum
Volume 9
Issue 1
10.3390/ECCM-10854
blsf-logo
Submit to this Journal
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Proceeding Paper

Risks Associated with the Use of Psychotropics in Patients Diagnosed with COVID-19 †

by
Francisco Rogério Cavalcante Mota Júnior
,
Victor Rannier Barreto de Oliveira
,
Victor Hugo Farias da Silva
and
Sávio Benvindo Ferreira
*
Academic Unit of Life Sciences (UACV), Center for Teacher Training (CFP), Federal University of Campina Grande (UFCG), Cajazeiras Campus 58.900-000, Paraíba, Brazil
*
Author to whom correspondence should be addressed.
†
Presented at the 1st International Electronic Conference on Clinical Medicine, 15–30 September 2021; Available online: https://eccm.sciforum.net/.
Biol. Life Sci. Forum 2021, 9(1), 4; https://doi.org/10.3390/ECCM-10854
Published: 15 September 2021
(This article belongs to the Proceedings of The 1st International Electronic Conference on Clinical Medicine)
Versions Notes

Abstract

In the context of the pandemic, negative implications for mental health have increased considerably, as well as the existing associations of psychotropics in this period to combat the new coronavirus. In view of this, the present integrative review aimed to verify the health impact of COVID-19 infection in patients with mental disorders who use psychotropics. As a result, the co-administration of these drugs represented a great risk at the systemic level, and can be lethal in certain cases. Thus, it is possible to conclude that patients with mental disorders taking psychotropic drugs are exposed to a greater risk of pharmacological interactions during COVID-19 treatment. That said, careful evaluations must be taken in order to implement an effective intervention that meets the needs of patients, always considering the risks of these drug associations.
Keywords: COVID-19; mental disorders; psychiatry; public health COVID-19; mental disorders; psychiatry; public health

Share and Cite

MDPI and ACS Style

Júnior, F.R.C.M.; Oliveira, V.R.B.d.; Silva, V.H.F.d.; Ferreira, S.B. Risks Associated with the Use of Psychotropics in Patients Diagnosed with COVID-19. Biol. Life Sci. Forum 2021, 9, 4. https://doi.org/10.3390/ECCM-10854

AMA Style

Júnior FRCM, Oliveira VRBd, Silva VHFd, Ferreira SB. Risks Associated with the Use of Psychotropics in Patients Diagnosed with COVID-19. Biology and Life Sciences Forum. 2021; 9(1):4. https://doi.org/10.3390/ECCM-10854

Chicago/Turabian Style

Júnior, Francisco Rogério Cavalcante Mota, Victor Rannier Barreto de Oliveira, Victor Hugo Farias da Silva, and Sávio Benvindo Ferreira. 2021. "Risks Associated with the Use of Psychotropics in Patients Diagnosed with COVID-19" Biology and Life Sciences Forum 9, no. 1: 4. https://doi.org/10.3390/ECCM-10854

APA Style

Júnior, F. R. C. M., Oliveira, V. R. B. d., Silva, V. H. F. d., & Ferreira, S. B. (2021). Risks Associated with the Use of Psychotropics in Patients Diagnosed with COVID-19. Biology and Life Sciences Forum, 9(1), 4. https://doi.org/10.3390/ECCM-10854

Article Metrics

Back to TopTop